ArticleNeuro-oncology2023
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Abstract read
In one paragraph
Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.International journal of molecular sciences · 2023Pooled it
- Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.Neuro-oncology · 2026Trial
- Vebreltinib for Previously Treated Astrocytoma,Cancer communications (London, England) · 2026Trial
- Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial.Nature communications · 2025Trial
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.The New England journal of medicine · 2023Trial
- Feasibility of High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumor and Young Adults With Isocitrate Dehydrogenase-Mutant Gliomas (HYPE): Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Article
- Spatial analysis reveals the evolving organization of IDH-mutant glioma.Cancer cell · 2026Article
- Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
- Modeling gliomas with organoids: Classification, fidelity, and guidelines for translational neuro-oncology.Neuro-oncology · 2026Review
- Expanding the molecular grading criteria in IDH-mutant astrocytoma.Neuro-oncology · 2026Article
- Validation of proposed cIMPACT-NOW update 12 molecular grading criteria for IDH-mutant astrocytoma.Acta neuropathologica · 2026Article
- NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- 1p/19q codeletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas.Neuro-oncology · 2026Article
- Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment.The patient · 2026Article
- Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.Journal of neuro-oncology · 2026Article
- Report of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification.Journal of neuro-oncology · 2026Observational
- Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma.Annals of clinical and translational neurology · 2026Article
106 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Julie J MillerStephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
L Nicolas Gonzalez CastroHarvard Medical School, Boston, MA, USA.ORCID 0000-0001-7699-5188
Samuel McBrayerChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, Texas, 75235, USA.
Michael WellerDepartment of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.ORCID 0000-0002-1748-174X
Timothy CloughesyUCLA Neuro-Oncology Program, Los Angeles, CA, USA.
Jana PortnowOncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Ovidiu AndronesiHarvard Medical School, Boston, MA, USA.
Jill S Barnholtz-SloanInformatics and Data Science (IDS), Center for Biomedical Informatics and Information Technology (CBIIT), Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Bethesda, MD, USA.
Brigitta G BaumertCantonal Hospital Graubunden, Institute of Radiation-Oncology, Chur, Switzerland.
Mitchell S BergerDepartment of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.ORCID 0000-0003-1983-4892
Wenya Linda BiHarvard Medical School, Boston, MA, USA.
Ranjit BindraDepartment of Therapeutic Radiology, Brain Tumor Center, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-3255-0467
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-2552-6546
Susan M ChangDepartment of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.
Joseph F CostelloDepartment of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.
Craig HorbinskiDepartment of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0001-8340-9992
Raymond Y HuangHarvard Medical School, Boston, MA, USA.
Robert B JenkinsIndividualized Medicine Research, Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota 55901, USA.ORCID 0000-0002-4049-694X
Keith L LigonHarvard Medical School, Boston, MA, USA.
Ingo K MellinghoffDepartment of Neurology, Evnin Family Chair in Neuro-Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
L Burt NaborsDepartment of Neurology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael PlattenCCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
David A ReardonHarvard Medical School, Boston, MA, USA.
Diana D ShiHarvard Medical School, Boston, MA, USA.
David SchiffDivision of Neuro-Oncology, Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA.
Wolfgang WickNeuro-Oncology at the German Cancer Research Center (DKFZ), Program Chair of Neuro-Oncology at the National Center for Tumor Diseases (NCT), and Neurology and Chairman at the Neurology Clinic in Heidelberg, Heidelberg, Germany.ORCID 0000-0002-6171-634X
Hai YanGenetron Health Inc, Gaithersburg, Maryland 20879, USA.
Andreas von DeimlingDepartment of Neuropathology, University Hospital Heidelberg, and, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and, DKTK, INF 224, 69120 Heidelberg, Germany.
Martin van den BentBrain Tumour Centre, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.
William G KaelinHarvard Medical School, Boston, MA, USA.
Patrick Y WenHarvard Medical School, Boston, MA, USA.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MThe von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8M3-D spatial approach to discover genomic effectors of immunosuppression during malignant transformationR01CA244838 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COSTELLO, JOSEPH F · 2020 to 2024
$2.7MNCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA244838NCI NIH HHS R35 CA210068
Abstract
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.
Indexed as
Brain NeoplasmsGliomaAdultConsensusHumansIsocitrate DehydrogenaseMutationIsocitrate DehydrogenaseD-2HGgliomaIsocitrate dehydrogenase (IDH)
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.